Identification of components in iodinated glycerol.

Iodinated glycerol (CAS no. 5634-39-9), therapeutically used as an expectorant and source of organically bound iodine, was analyzed to determine the purity and composition of the chemical samples used in carcinogenicity and toxicity studies. The manufactured product is described by the patent and chemical literature as a mixture of two isomeric iodopropylideneglycerols (structures 1 and 2). The results of our studies, however, indicate that the two principal components of the product were 3-iodo-1,2-propanediol (IPD) and glycerol (GLY). Analyses from GC-MS (full scan electron impact) and carbon-13 nuclear magnetic resonance spectrometry provided conclusive identification of these components. The quantification of IPD and GLY in one of two samples of commercial product using GC-flame ionization detection indicated concentrations of 33 and 17%, respectively (Sample A). Similar concentrations were determined for a second sample from the same source (Sample B), which was a gratis sample procured approximately nine years after Sample A. Numerous minor components were also observed in these two samples. These components were tentatively identified as condensation products of glycerol and iodine-containing analogues. The iodopropylideneglycerol compounds, described in the patent, were not observed in either of the two samples.

Toxicokinetics of oxazepam in rats and mice.

The comparative toxicokinetics of oxazepam were studied in F344 rats, B6C3F1 mice, and Swiss-Webster mice of both sexes after an i.v. dose of 20 mg/kg and oral gavage doses of 50, 200, and 400 mg/kg. In addition, the toxicokinetics of oxazepam in a 3-week dosed-feed study of male B6C3F1 mice at 125 and 2500 ppm were also investigated. Results indicated that the elimination of oxazepam from plasma after i.v. injection in both rats and mice were first-order and could be best described by a two-compartment model with a terminal elimination half-life of 4-5 h for rats and 5-7 h for mice. After oral gavage dosing the peak oxazepam plasma concentrations in most rodents were reached within 2-3.5 h. At all doses studied, female rodents had significantly higher plasma concentrations than males. Absorption of oxazepam was significantly extended at higher oral doses of 200 and 400 mg/kg. At 50 mg/kg, the bioavailability of oxazepam in rats (< 50%) was lower than in Swiss-Webster mice (> 80%). The bioavailability of oxazepam in both B6C3F1 and Swiss-Webster mice decreased with increasing dose. A dose proportionality of Cmax was not observed in rats and mice after gavage doses of 50, 200, and 400 mg/kg. Plasma concentrations of oxazepam in the dosed-feed study increased with the concentration of oxazepam in the feed, a quasi-steady-state of plasma concentrations of oxazepam was reached after approximately 4 days ad libitum exposure. In B6C3F1 mice, the estimated relative bioavailability of oxazepam from dosed feed (relative to gavage study at 50 mg/kg) was about 43%.

Rapid determination of low pg/mg amounts of N-nitrosodimethylamine in rodent body fluid and tissue samples by low resolution mass spectrometry.

A rapid, sensitive, specific, and cost-effective method for the determination of N-nitrosodimethylamine (NDMA) in rodent tissue and body fluid samples is reported. The method involves isolation of the NDMA from the samples with subsequent detection and quantitation of observed NDMA against a mass labeled N-[15N]nitrosodimethyl-[15N]amine ([15N]NDMA) internal standard by capillary gas chromatography/mass spectrometry with selected ion monitoring. Validation of the method includes linearity studies of NDMA response, calculation of the relative response factor (RRF) for NDMA vs. [15N]NDMA, and absolute recovery studies. Estimates of precision, detection limit, and minimum quantifiable limit are also reported.

Determination of L-buthionine-(S,R)-sulfoximine in plasma by high-performance liquid chromatography with o-phthalaldehyde derivatization and fluorometric detection.

The development of a high-performance liquid chromatography system for the analysis of L-buthionine-(S,R)-sulfoximine (BSO) in human plasma is described. o-Phthalaldehyde derivatization and fluorescence detection were used. The R- and S-BSO peaks were partially separated from each other and completely separated from the matrix components. The limit of detection for BSO was 2 micrograms/ml plasma.

Pancreatic metabolism of benzo(a)pyrene in vitro and in vivo in the Long-Evans rat.

The in vitro metabolism of benzo(a)pyrene was compared between pancreas and liver with and without pretreatment. There was no significant difference in metabolic pathways between the two tissues. Evidence for induction of the metabolism was evident following 3-methyl-cholanthrene pretreatment. Temporal studies demonstrated rapid elimination of BP from the tissues within the first 5 hours with possible recirculation of metabolites 22 hours after injection of the carcinogen. There was significant binding of BP to DNA in pancreas and liver at 5 hours.

Metabolism of 3-methylcholanthrene in rat pancreas.

In vitro and in vivo studies revealed that pancreases of Long-Evans male rats metabolized 3-methylcholanthrene (3MC) principally at the 1- and 2-carbon positions. The pancreatic metabolizing capability was not induced by pretreatment with either benzo(a)pyrene (BP) or phenobarbital (PB). During the period of observation from 5 to 48 hr, the maximum tissue content of radioactivity observed in the in vivo studies occurred at 16 hr after injection of 3MC in both liver and pancreas. Pancreatic tissue retained about four times more carcinogen per gram of tissue than liver tissues at all time periods.

Metabolism of a carcinogen (7,12-dimethylbenzanthracene) in the pancreas of the Long-Evans rat.

Because of the high incidence of pancreatic cancer in the United States and because of the correlation of pancreatic cancer to environmental exposure, we have undertaken experiments to measure the metabolism of the carcinogen 7,12-dimethylbenzanthracene in the pancreas of the Long-Evans male rat. This study examined the in vitro metabolism of the carcinogen and found the production of aqueous products in pancreas to be similar to that in liver, however, the pancreatic capability was not induced to greater metabolism by pretreatment with either phenobarbital or 3-methylcholanthrene. High pressure liquid chromatographic analysis of the in vitro products of pancreatic metabolism demonstrated a relatively greater abundance of 5,6-epoxy-7-hydroxymethyl-12-methylbenzanthracene than the liver and a relatively less abundance of 7-hydroxymethyl-12-methylbenzanthracene and 7-methyl-12-hydroxymethylbenzanthracene than the liver. Carcinogen levels were measured in pancreas, liver, bile and blood at 2, 5, 10, 16, 22 and 36 hours after injection.

Chemical characterization of psoralens used in the National Toxicology Program research projects.

Chemical analyses of 4 psoralen derivatives were performed with the use of various techniques, including thin-layer chromatography, gas chromatography, infrared and nuclear magnetic resonance spectroscopy. 8-Methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, and 5-methylisopsoralen were determined to be 99, 93, 97, and 99% pure, respectively. A 7% contaminant in the 5-methoxypsoralen sample was identified as a dimethoxypsoralen isomer. These psoralens are being used in research projects sponsored by the National Toxicology Program.

Comparative human study of ibuprofen enantiomer plasma concentrations produced by two commercially available ibuprofen tablets.

Twelve healthy male subjects participated in a two-way Latin square crossover study in which the treatments were a single 400 mg generic ibuprofen tablet (Tablet A) or a single 400 mg MOTRIN Tablet (Tablet B). Blood samples were drawn at various times through 12 h after dosing and plasma samples were assayed for ibuprofen enantiomers with a stereospecific capillary gas chromatographic procedure. Concentration-time data for both enantiomers were in agreement and indicated that drug was absorbed much more quickly from Tablet B than from the Tablet A; enantiomer Tmax values were less than 1.3 h from Tablet B but longer than 4 h from the Tablet A (p less than 0.001). Also, maximum enantiomer plasma concentrations from the Tablet B were about 50 per cent of the peak concentrations observed from Tablet A (p less than 0.001). The total extent of drug absorption appeared to be the same in both products. These data clearly indicate that the two tablets are not bioequivalent with respect to either ibuprofen enantiomer.

Comparison of the analysis of delta 9-tetrahydrocannabinol capsules by high-performance liquid chromatography and capillary gas chromatography.

The modification of a high-performance liquid chromatography (HPLC) system and the development of a capillary gas-chromatographic (GC) system for the analysis of delta 9-tetrahydrocannabinol, encapsulated in soft gelatin capsules, are described. A photodiode array detector was used to evaluate peak homogeneity after each HPLC system modification. Sesame oil was separated from the extract by Sep-Pak filtration prior to GC analysis. Quantitation by both systems had r values greater than 0.999 and R.S.D. values less than 1.0%. Simultaneous capsule assays by both methods agreed within 1%.

Glucuronidation of lipophilic substrates: preparation of 3-benzo[a]pyrenyl-beta-D-glucopyranosiduronic acid in multimilligram quantities by microsomal UDP-glucuronyl transferase.

A convenient method for the enzymic conversion of multimilligram quantities of 3-hydroxybenzo[a]pyrene to 3-benzo[a]pyrenyl-beta-D-glucopyranosiduronic acid in 90% yield is described. Commercially available freeze-dried rabbit liver microsomes were incubated in the presence of UDPGA, 3-hydroxybenzo[a]pyrene, and Triton X-100 detergent (Figure 1). The course of the biosynthetic reaction was followed by fluorimetry. The glucuronide product was extracted from the acidified incubation supernate with ethyl acetate and the acid function of the glucuronide was utilized in an acid-base extraction procedure to purify the glucuronide from biological and unreacted starting material. The glucuronide precipitated from ethyl acetate and was collected by centrifugation. High pressure liquid chromatography and spectroscopic techniques were used to verify the structure and purity of 3-benzo[a]pyrenyl-beta-D-glucopyranosiduronic acid.

Toxicokinetics of pentachlorophenol in the F344 rat. Gavage and dosed feed studies.

1. The toxicokinetics of pentachlorophenol (PCP) were studied in the Fischer 344 rat using i.v. and oral (gavage, dosed feed) routes of exposure. 2. Only minor sex differences were observed in the elimination kinetics of PCP after i.v. administration at 5 mg/kg. 3. Absorption of PCP from the gastrointestinal tract after gavage doses of 9.5 and 38 mg/kg in aqueous methylcellulose vehicles was first order with an absorption half-life of about 1.3 h. 4. The absorption rate constant of PCP from doses feed was comparable with that obtained from aqueous methylcellulose gavage formulations. 5. Bioavailability of PCP administered in dosed feed was significantly lower than the bioavailability of PCP administered by gavage. 6. Dose proportionality was established to a dosage of at least 38 mg/kg. 7. Daily fluctuation of PCP plasma concentrations was observed during the dosed feed study with peak and trough concentrations occurring in early morning and late afternoon, respectively. 8. The time course of PCP plasma concentrations during the dosed feed study were simulated using a computer model based on linear theory. The simulations were comparable with the experimentally determined concentrations.

Toxicokinetics of pentachloroanisole in F344 rats and B6C3F1 mice.

1. Toxicokinetics of pentachloroanisole (PCA) were studied in F344 rat and B6C3F1 mouse of both sexes by gavage at doses of 10, 20 and 40 mg/kg and by i.v. at 10 mg/kg. 2. PCA was rapidly demethylated to pentachlorophenol (PCP) in both rat and mouse and the resulting PCP plasma concentrations were much higher than that of parent PCA due to the much smaller apparent volume of distribution of PCP. 3. Peak plasma concentrations of PCA and PCP increased with dose in both rat and mouse. 4. Bioavailability of PCA was low in both rat and mouse and was sex independent. 5. The high plasma concentrations and relatively long biological half-life of PCP in both species after both i.v. and oral dosing with PCA indicate possible bioaccumulation of PCP upon multiple oral administrations of PCA.

Preparation, isolation, analysis, and characterization of 3-benzo[a]pyrenyl-beta-D-glucopyranosiduronic acid: a metabolite of 3-hydroxybenzo[a]pyrene with potentially high carcinogenic activity.

The aglycone, 3-hydroxybenzo[a]pyrene, was metabolized to 3-benzo[a]pyrenyl-beta-D-glucopyranosiduronic acid in the presence of uridine 5'-diphosphoglucuronic acid and rabbit liver microsomes. The course of the biosynthetic reaction was followed by fluorimetry and reverse-phase, paired-ion high pressure liquid chromatography (HPLC). Also, the HPLC system was used to analyze for glucuronide and 3-hydroxybenzo[a]pyrene during the isolation procedure. The existence of a glucuronide of 3-hydroxybenzo[a]pyrene was determined by radiotracer and enzymic techniques, utilizing the HPLC system. Field desorption and direct inlet mass spectral techniques were used to characterize the 3-hydroxybenzo[a]pyrene glucuronide.